Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF N486_T491delinsK||lymphatic system cancer||predicted - sensitive||MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor||Cobimetinib||Case Reports/Case Series||Actionable||In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Langerhans cell histiocytosis harboring BRAF N486_T491delinsK (PMID: 30867592; NCT01953926).||30867592|
|BRAF N486_T491delinsK||Advanced Solid Tumor||predicted - sensitive||MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor||Cobimetinib||Preclinical - Cell culture||Actionable||In a preclinical study, Cotellic (cobimetinib) inhibited viability of transformed cells expressing BRAF N486_T491delinsK in culture (PMID: 30867592).||30867592|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|